Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

An Akero Therapeutics drug in development for the fatty liver disease MASH now has clinical trial results showing the experimental treatment reversed organ scarring, bringing patients back from an ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...

Akero Therapeutics (AKRO) stock soared 115% after the company reported positive long-term results from a Phase 2b study of ...

Akero Therapeutics CEO and president Andrew Cheng said: “We believe today’s first-ever public report of reversal of cirrhosis ...

Citi analyst Jonathan Woo says Akero Therapeutics (AKRO)’ 96-week data update from its SYMMETRY trial of efruxifermin for patients with ...